Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3276
AquaBounty Technologies
AQB
$7.72M
| $125K | ﹤0.01% |
+2,885
| New | +$130K |
|
|
CREG
3277
DELISTED
Smart Powerr
CREG
| $124K | ﹤0.01% |
441
+24
| +6% | +$7.51K |
|
3278
Caledonia Mining Corp
CMCL
$439M
| $123K | ﹤0.01% |
14,656
+168
| +1% | +$1.31K |
|
|
SGRP
3279
DELISTED
SPAR Group
SGRP
| $123K | ﹤0.01% |
94,800
+52,800
| +126% | +$60K |
|
|
AHPI
3280
DELISTED
Allied Healthcare Products
AHPI
| $123K | ﹤0.01% |
101,082
+3,442
| +4% | +$3.96K |
|
3281
Myomo
MYO
$57.8M
| $122K | ﹤0.01% |
13,464
+4,651
| +53% | +$74.1K |
|
3282
Tandy Leather Factory
TLF
$20.6M
| $122K | ﹤0.01% |
21,400
+1,000
| +5% | +$5.02K |
|
3283
Archrock
AROC
$5.85B
| $121K | ﹤0.01% |
12,100
-168,800
| -93% | -$1.57M |
|
3284
Liquidia Corp
LQDA
$6.45B
| $121K | ﹤0.01% |
28,197
-9,703
| -26% | -$38.9K |
|
3285
Seanergy Maritime Holdings
SHIP
$360M
| $121K | ﹤0.01% |
1,383
-57
| -4% | -$5.02K |
|
|
ATXI
3286
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $121K | ﹤0.01% |
+11
| New | +$76.9K |
|
|
MARK
3287
DELISTED
Remark Holdings, Inc.
MARK
| $121K | ﹤0.01% |
23,571
+2,690
| +13% | +$18.5K |
|
|
BCOM
3288
DELISTED
B Communications Ltd
BCOM
| $121K | ﹤0.01% |
67,516
+4,700
| +7% | +$7.3K |
|
3289
Dyadic International
DYAI
$28.1M
| $120K | ﹤0.01% |
+23,200
| New | +$139K |
|
3290
Cerus
CERS
$572M
| $119K | ﹤0.01% |
+28,266
| New | +$122K |
|
|
EVLO
3291
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $119K | ﹤0.01% |
1,460
+735
| +101% | +$82.2K |
|
3292
CBAK Energy Technology Ltd
CBAT
$65.5M
| $118K | ﹤0.01% |
102,766
-12,854
| -11% | -$9.3K |
|
|
JG
3293
Aurora Mobile
JG
$31.3M
| $118K | ﹤0.01% |
2,006
+1,035
| +107% | +$68.3K |
|
3294
VOC Energy
VOC
$55.8M
| $118K | ﹤0.01% |
+25,521
| New | +$123K |
|
|
ACCS
3295
ACCESS Newswire
ACCS
$18.7M
| $118K | ﹤0.01% |
+10,101
| New | +$113K |
|
|
NHLD
3296
DELISTED
National Holdings Corporation
NHLD
| $118K | ﹤0.01% |
46,203
+2,900
| +7% | +$7.75K |
|
3297
TDH Holdings
PETZ
$15.5M
| $115K | ﹤0.01% |
4,256
-765
| -15% | -$22.9K |
|
|
GSV
3298
DELISTED
Gold Standard Ventures Corp.
GSV
| $114K | ﹤0.01% |
+132,684
| New | +$99.5K |
|
3299
CLPS Inc
CLPS
$26.1M
| $113K | ﹤0.01% |
22,500
+6,700
| +42% | +$27.1K |
|
3300
Sutro Biopharma
STRO
$353M
| $113K | ﹤0.01% |
+1,030
| New | +$106K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.